Author of

• 20182

  +

  P3.03 - Chemotherapy/Targeted Therapy (ID 719)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24046

    +

    P3.03-001 - Immunotherapy Toxicity: Are General Practitioner Satisfied About Information Transmitted? A Retrospective Survey (ID 9998)

    09:30 - 09:30  |  Author(s): F. Divanon
    • Abstract

    Background:
    Nivolumab is an immune check point inhibitor becoming a major tool in the treatment of Non-Small cell lung cancer (NSCLC). Its side effects are specific from its pharmacological class. General practitioners (=GP) may manage cancer patients and they would like to receive information about side effects of anticancer drugs. In our cancer center three oncologists prescribe nivolumab for NSLC. They use three different methods to inform the GP about Nivolumab expected side effects: a letter directly for the GP, an information sheet and/or a personal drug's card (OPDIVO® card) given to the patients. A survey has been conducted to assess GP satisfaction of information.
    
    Method:
    A complete list of all patients treated by nivolumab since its commercialization was obtained by medical prescription writing software (CHIMIO). Their GP have been identified with computer-based patient record (DX-Care). Through this same process, any information given about nivolumab side effects has been queried. A questionnaire has been drawn up, made up of 4 open questions and 1 closed question. All GP have been contacted by phone.
    
    Result:
    121 patients have been identified. 5 patients were excluded because they died a few days after the first administration or because we could not find their GP. 103 GP were phoned over a one-month period and 86 GP responded to the survey. GP received 63 Nivolumab side effects letters and patients received 31 information sheets and 2 OPDIVO® cards. For 18 patients there was no evidence of information transmission. According to the survey, only 9 GP received information. For six of them in a letter, for two in an information sheet, and for one a patient showed its OPDIVO® card. They were satisfied with information. Most GP would like to be informed by secure messaging.
    
    Conclusion:
    No evidence of information was found in 21% of the electronic patient care. In the future, information must appear for all patients. Only 10% of GP could remember to have information, this may be partly explained by recall bias. As regards the desired method, they were different views. It was decided to harmonize oncologist practices. Nivolumab side effects are now systematically described in the letter for GP. All patients receive two information sheets with an OPDIVO® card. Patients are instructed to make an appointment with their GP to give one information sheet. In this way, we reinforce the communication between the hospital and the GP and thus hope to optimize patient’s care